OncoMatch/Clinical Trials/NCT06676449
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Is NCT06676449 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Immunotherapy and chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens for esophageal carcinoma.
Treatment: Immunotherapy · chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens — The goal of this clinical trial is to learn if immunotherapy in combination with tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) and chemotherapy works to treat locally advanced esophageal squamous cell cancer in adults. Researchers will compare immunotherapy in combination with TDLN-sparing RT and chemotherapy to TDLN-sparing RT and chemotherapy to see if immunotherapy works more effectively when using TDLN-sparing RT to treat locally advanced esophageal squamous cell cancer Participants will: TDLN-sparing RT for esophageal cancer 50.4Gy/28Fx Paclitaxel plus cisplatin every 3 weeks for 4 cycles PD-1 inhibitors or observation every 3 weeks for 1 year
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T2-4N0M0, TXN+M0, TXNXM1 (ONLY FOR SUPRACLAVICULAR LYMPH NODES METASTASIS) (8th UICC-TNM classification)
Clinical stages T2-4N0M0 or TxN+M0 or TxNxM1 (Only for supraclavicular lymph nodes metastasis) based on the 8th UICC-TNM classification
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Absolute neutrophil counts (ANC) ≥1.5×10^9⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×10^9⁄L
Kidney function
Creatinine ≤1.5 ULN
Liver function
Total bilirubin ≤1.5 upper limit of normal (ULN); AST ≤2.5 ULN; ALT ≤2.5 ULN
Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×10^9⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×10^9⁄L; Total bilirubin ≤1.5 upper limit of normal (ULN); Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine ≤1.5 ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify